Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells

International Journal of Cancer

Volumn 124, Issue 12, 2009, Pages 2845-2854

  Li, Mengsen ^a,b   Li, Hui ^a   Li, Chaoying ^a   Zhou, Sheng ^b   Guo, Liyuan ^a   Liu, Han ^a   Jiang, Wei ^a   Liu, Xinhua ^a   Li, Pingfeng ^a   McNutt, Michael A ^a   Li, Gang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

All trans retinoic acid; Alpha fetoprotein; Apoptosis; Caspase 3; Hepatocellular carcinoma cells; TNF related apoptosis inducing ligand

Indexed keywords

ALPHA FETOPROTEIN; CASPASE 3; CASPASE 8; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETINOIC ACID; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ATBF1A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETICS; IMMUNOPRECIPITATION; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; IMMUNOPRECIPITATION; LIVER NEOPLASMS; PROTEIN TRANSPORT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 65649086739     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24272     Document Type: Article

References (41)

1. Gotoh M, Nakatani T, Masuda T, Mizuguchi Y, Sakamoto M, Tsuchiya R, Kato H, Furuta K. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol 2003;33:522-526 (Pubitemid 43115246)
2. Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H, Kaneko S. Ephrin-A1 expression contributes to the malignant characteristics of alpha-fetoprotein producing hepatocellular carcinoma. Gut 2005;54:843-851 (Pubitemid 40732104)
3. Ishigami S, Natsugoe S, Nakashima H, Tokuda K, Nakajo A, Okumura H, Matsumoto M, Nakashima S, Hokita S, Aikou T. Biological aggressiveness of alpha-fetoprotein (AFP)-positive gastric cancer. Hepatogastroenterology 2006;53:338-341 (Pubitemid 43954402)
4. Mizejewski GJ, MacColl R. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. Mol Cancer Ther 2003;2:1243-1255
5. Vakharia D, Mizejewski GJ. Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. Breast Cancer Res Treat 2000;63:41-52. (Pubitemid 30786990)
6. Muehlemann M, Miller KD, Dauphinee M, Mizejewski GJ. Review of growth inhibitory peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis. Cancer Metastasis Rev 2005;24:441-467 (Pubitemid 41569983)
7. Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol 2004;10:819-824 (Pubitemid 38418353)
8. Li MS, Liu XH, Zhou S, Li PF, Li G. Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes. BMC Cancer 2005;5:96. (Pubitemid 41461039)
9. Li MS, Zhou S, Liu XH, Li PF, McNutt MA, Li G. Alpha-fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Lett 2007;249:227-234 (Pubitemid 46452932)
10. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163 (Pubitemid 29068521)
11. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Masters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
12. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75. (Pubitemid 36511833)
13. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber N, Herzer K, Walczak H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005;42: 588-597 (Pubitemid 41233651)
14. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002;34:114-122 (Pubitemid 34664327)
15. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22:7305-7315 (Pubitemid 37487162)
16. Dauphinee MJ, Mizejewski GJ. Human alpha-fetoprotein contains potential heterodimerization motifs capable of interaction with nuclear receptors and transcript ion/growth factors. Med Hypotheses 2002;58:453-461 (Pubitemid 35041842)
17. Fernandez-Luna JL. Apoptosis regulators as targets for cancer therapy. Clin Transl Oncol 2007;9:555-562
18. Xu J, Li PF, Liu XH, Li G. Morphine aggravates the apoptosis of simian immunodeficiency virus infected CEM x174 cells in the prolonged culture in vitro. Int Immunopharmacol 2004;4:1805-1816 (Pubitemid 39504821)
19. Wei EM, Li PF, Liu XH, Qian CW, Li H, Xia WY, Li G. The potential promoter regions on the 5′ flank sequence of the mu opioid receptor gene in lymphocytes. J Cell Biochem 2005;95:1204-1213 (Pubitemid 41420127)
20. Galperin E, Verkhusha V, Sorkin A. Three-chromophore FRET microscopy to analyze multiprotein interactions in living cells. Nat Methods 2004;1:209-217
21. Li H, Liu H, Wang Z, Liu X, Guo L, Huang L, Gao L, McNutt MA, Li G. The role of transcription factors Sp1 and YY1 in proximal promoter region in initiation of transcription of the mu opioid receptor gene in human lymphocytes. J Cell Biochem 2008;104:237-250
22. Kojima S, Okuno M, Matsushima-Nishiwaki R, Friedman SL, Moriwaki H. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma. Int J Oncol 2004;24:797-805 (review).
23. Nagane M, Pan GH, Weddle JJ, Dixit VM, Cavenee WK, Huang HJS. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-853 (Pubitemid 30129513)
24. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734-741 (Pubitemid 29076075)
25. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
26. Wang LH, Levin MS. Suppression of FGF signaling: a putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma. Gastroenterology 2005;128:228-231 (Pubitemid 40039974)
27. Clerici C, Castellani D, Russo G, Fiorucci S, Sabatino G, Giuliano V, Gentili G, Morelli O, Raffo P, Baldoni M, Morelli A, Toma S. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. Anticancer Res 2004;24:1255-1260 (Pubitemid 38624971)
28. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23:8093-8108 (Pubitemid 46657412)
29. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999;11:68-75. (Pubitemid 29082059)
30. Hickman JA. Apoptosis and tumourigenesis. Curr Opin Genet Dev 2002;12:67-72. (Pubitemid 34094992)
31. Shi YG. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 2004;13:1979-1987 (Pubitemid 38989605)
32. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60: 7149-7155
33. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004;40:609-617 (Pubitemid 39265582)
34. Dudich E, Semenkova L, Dudich I, Denesyuk A, Tatulov E, Korpela T. Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction. FEBS J 2006;273:3837-3849 (Pubitemid 44166662)
35. Semenkova L, Dudich E, Dudich I, Tokhtamisheva N, Tatulov E, Okruzhnov Y, Garcia-Foncillas J, Palop-Cubillo JA, Korpela T. Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. Eur J Biochem 2003;270:4388-4399 (Pubitemid 37340357)
36. Jeng YM, Hsu HC. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett 2002;181:205-208 (Pubitemid 34518305)
37. Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, Fleischer B, Trauhwein C, Michalski C, Schulze-Bergkamen H, Friess H, Stremmel W, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006;66:7059-7066 (Pubitemid 44197682)
38. Kataoka H, Joh T, Ohshima T, Itoh Y, Senoo K, Yokoyama Y, Tada T, Miura Y, Asai K, Itoh M. Alpha-fetoprotein producing gastric cancer cells lack transcription factor AT-motif binding factor 1 (ATBF1). Gastroenterology 2001;120:A31-A.
39. Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M, Segal-Bendirdjian E. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 2004;23:7469-7474 (Pubitemid 39389688)
40. Won YS, Lee SW. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA. J Biotechnol 2007;129:614-619 (Pubitemid 46590452)
41. Zhang H, Bai ZL, Chen J, Wang Z, Li J. Alpha-fetoprotein-specific transfer factors downregulate alpha-fetoprotein expression and specifically induce apoptosis in Bel7402 alpha-fetoprotein-positive hepatocarcinoma cells. Hepatol Res 2007;37:557-567 (Pubitemid 46864252)